{"filing":{"accession_number":"0001104659-26-068615","cik":"0001512762","ticker":"CHRS","company_name":"Coherus Oncology, Inc.","form":"8-K","filing_date":"2026-06-01","report_date":null,"primary_document":"chrs-20260527x8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1512762/000110465926068615/chrs-20260527x8k.htm"},"events":[{"id":7707,"run_id":6771,"accession_number":"0001104659-26-068615","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"This is a classic Item 5.07 disclosure of shareholder vote results from Coherus Oncology's 2026 Annual Meeting held May 27–29, 2026. The filing reports voting outcomes for five proposals: election of two Class III directors (Dennis M. Lanfear and Mats L. Wahlström), ratification of Ernst \u0026 Young LLP as auditor, a Say-on-Pay advisory vote, approval of stock option exercise price reduction, and approval of an increase in shares reserved under the equity incentive plan. These results are material to investors as they reflect stockholder approval of governance, compensation, and capital allocation matters.","company_name":"Coherus Oncology, Inc.","ticker":"CHRS","filing_date":"2026-06-01","form":"8-K","submitted_at":null,"items":[{"id":3013,"accession_number":"0001104659-26-068615","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a classic Item 5.07 disclosure of shareholder vote results from Coherus Oncology's 2026 Annual Meeting held May 27–29, 2026. The filing reports voting outcomes for five proposals: election of two Class III directors (Dennis M. Lanfear and Mats L. Wahlström), ratification of Ernst \u0026 Young LLP as auditor, a Say-on-Pay advisory vote, approval of stock option exercise price reduction, and approval of an increase in shares reserved under the equity incentive plan. These results are material to investors as they reflect stockholder approval of governance, compensation, and capital allocation matters.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-02T02:15:20.217997+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":3013,"accession_number":"0001104659-26-068615","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a classic Item 5.07 disclosure of shareholder vote results from Coherus Oncology's 2026 Annual Meeting held May 27–29, 2026. The filing reports voting outcomes for five proposals: election of two Class III directors (Dennis M. Lanfear and Mats L. Wahlström), ratification of Ernst \u0026 Young LLP as auditor, a Say-on-Pay advisory vote, approval of stock option exercise price reduction, and approval of an increase in shares reserved under the equity incentive plan. These results are material to investors as they reflect stockholder approval of governance, compensation, and capital allocation matters.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-02T02:15:20.217997+00:00","company_name":"Coherus Oncology, Inc.","ticker":"CHRS","filing_date":"2026-06-01"}]}